Drug intelligence / Profile preview

ArthroPaint

Development stage: Preclinical
Lead developer: Cells for Cells
Modality: Cell Therapies
Administration: Arthroscopic Application

Overview

ArthroPaint is a medical device and regenerative bioink system developed by Cells for Cells in partnership with MedXCell. It is designed for the direct, in situ 3D bioprinting of living tissues to repair articular cartilage defects in the knee and ankle. The system utilizes a specialized arthroscopic applicator to deliver bioinks with regenerative capabilities directly to the lesion site, allowing for controlled deposition and faithful reconstruction of subchondral bone and hyaline cartilage. This minimally invasive approach aims to provide a definitive solution for complete restoration of damaged cartilage while ensuring reproducibility of clinical results.

Brand names: ArthroPaint
Other names: Arthropaint

Beyond the preview

Go deeper on ArthroPaint.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ArthroPaint.

Explore the full profile